RxDoctor Payments Data

Peter Shaftel, MD

Interventional Cardiology · Meadowbrook, PANPI 1447242011

Payments from drug & device makers

$7,893in general payments, 2019–2025

Across 464 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$799
  • Johnson & Johnson$784
  • Boston Scientific$738
  • Pfizer$663
  • E.r. Squibb & Sons, L.L.C.$651
  • Amgen$628
  • plus $4K from 31 others

What the payments were for

  • Food & beverage$7,885100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,893 in reported general payments places this provider in the 45th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$179,802
Medicare patients
544
Services billed
2,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$170,305
XareltoRivaroxaban66$63,738
EntrestoSacubitril/Valsartan24$34,420
Repatha SureclickEvolocumab17$20,292
VascepaIcosapent Ethyl23$18,332
BrilintaTicagrelor14$11,197
JardianceEmpagliflozin11$9,784
Icosapent Ethyl19$9,114
Rosuvastatin Calcium190$4,099
Nebivolol Hcl36$2,845
Metoprolol Succinate134$2,374
Atorvastatin Calcium160$2,158
Carvedilol164$1,978
Ezetimibe79$1,829
Valsartan22$1,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$663$170,305162 claims
Johnson & JohnsonXarelto$784$63,73866 claims
NovartisEntresto$799$34,42024 claims
AstraZenecaBrilinta$603$11,19714 claims
Boehringer IngelheimJardiance$160$9,78411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Meadowbrook

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →